EDITORIALS

A challenge to integrity in spine publications: years of living dangerously with the promotion of bone growth factors

Eugene J. Carragee, MD, Alexander J. Ghanayem, MD, Bradley K. Weiner, MD, David J. Rothman, PhD, Christopher M. Bono, MD

Physician-directed (off-label) use of recombinant bone morphogenic protein-2: let us do it well!

Charles L. Branch, Jr., MD

REVIEW ARTICLE

A critical review of recombinant human bone morphogenetic protein-2 trials in spinal surgery: emerging safety concerns and lessons learned

Eugene J. Carragee, MD, Eric L. Hurwitz, DC, PhD, Bradley K. Weiner, MD

COMMENTARIES

Commentary: Resetting standards for sponsored research: do conflicts influence results?

Dan M. Spengler, MD

Commentary: Folly of FDA-approval studies for bone morphogenetic protein

Sohail K. Mirza, MD, MPH

REVIEW ARTICLE

Bone morphogenetic protein-2 and spinal arthrodesis: the basic science perspective on protein interaction with the nervous system

Anton E. Dmitriev, PhD, Ronald A. Lehman, Jr., MD, Aviva J. Symes, PhD

COMMENTARY

Commentary: Important considerations on bone morphogenetic protein-2 and neuroinflammation

Michael H. Heggeness, MD, PhD

Cover illustration from a photograph courtesy of Cory Garfin.
CLINICAL STUDIES

Adjacent vertebral body osteolysis with bone morphogenetic protein use in transfominal lumbar interbody fusion .................................................................507
Melvin D. Helgeson, MD, Ronald A. Lehman, Jr, MD, Jeanne C. Patzkowski, MD,
Anton E. Dmitriev, PhD, MSc, Michael K. Rosner, MD, Andrew W. Mack, MD

Retrograde ejaculation after anterior lumbar interbody fusion using rhBMP-2: a cohort controlled study........................................................................511
Eugene J. Carragee, MD, Kyle A. Mitsunaga, MD, Eric L. Hurwitz, DC, PhD,
Gaetano J. Scuderi, MD

COMMENTARIES

Commentary: Another complication associated with rhBMP-2?............................................................517
James D. Kang, MD

Commentary: An evolving perception of the risk of rhBMP-2 use for anterior spinal interbody fusions............................................................................520
Tomislav Smoljanovic, MD, PhD, Ivan Bojanic, MD, PhD

CLINICAL STUDIES

Complications with recombinant human bone morphogenetic protein-2 in posterolateral spine fusion associated with a dural tear.................................................................522
Steven D. Glassman, MD, Jeffrey L. Gum, MD, Charles H. Crawford III, MD,
Christopher B. Shields, MD, Leah Y. Carreon, MD, MSc

Promoting fusion in minimally invasive lumbar interbody stabilization with low-dose bone morphogenic protein-2—but what is the cost?..........................527
Richard J. Mannion, FRCS, PhD, Adrian M. Nowitzke, FRACS, Martin J. Wood, FRACS

Posterior iliac crest pain after posterolateral fusion with or without iliac crest graft harvest........................534
Jennifer M. Howard, MPH, Steven D. Glassman, MD, Leah Y. Carreon, MD, MSc

COMMENTARY

Commentary: Iliac crest bone graft: are the complications overrated? ......................................................538
Serena S. Hu, MD

TECHNICAL REPORT

Local bone graft harvesting and volumes in posterolateral lumbar fusion: a technical report........540
Eugene J. Carragee, MD, Garet C. Comer, MD, Micah W. Smith, MD

BASIC SCIENCE

An injectable method for noninvasive spine fusion .................................................................................545
Ronke M. Olabisi, PhD, ZaWauunya Lazard, BS, Michael H. Heggeness, MD, PhD,
Kevin M. Moran, MD, John A. Hipp, PhD, Ashvin K. Dewan, MD, Alan R. Davis, PhD,
Jennifer L. West, PhD, Elizabeth A. Olmsted-Davis, PhD

COMMENTARY

Commentary: Gene therapy for spinal fusion.........................................................................................557
Jeffrey C. Wang, MD
BASIC SCIENCE

Biomimetic calcium phosphate coatings as bone morphogenetic protein delivery systems in spinal fusion..................................................560
Kamran Majid, MD, Michael D. Tseng, MD, Kevin C. Baker, MS, Alma Reyes-Trocchia, MD,
Harry N. Herkowitz, MD

Bone morphogenetic protein–binding peptide reduces the inflammatory response to recombinant human bone morphogenetic protein-2 and recombinant human bone morphogenetic protein-7 in a rodent model of soft-tissue inflammation..............................................568
Kwang-Bok Lee, MD, PhD, Samuel S. Murray, MD, Cyrus E. Taghavi, MD, Kyung-Jin Song, MD,
Elsa J. Brochmann, PhD, Jared S. Johnson, MD, Gun Keorochana, MD, Jen-Chung Liao, MD,
Jeffrey C. Wang, MD

JOURNAL REPORTS

Journal Reports .............................................................................................................................................577

IMAGES OF SPINE CARE

Vertebral body osteolysis after minimal-access transforaminal interbody fusion ..............................................581
Ronald A. Lehman, Jr., MD

Meetings Calendar ........................................................................................................................................583

Financial Conflict of Interest Disclosure Key

Level A. $100 to $1000
Level B. $1,001 to $10,000
Level C. $10,001 to $25,000
Level D. $25,001 to $50,000
Level E. $50,001 to $100,000
Level F. $100,001 to $500,000
Level G. $500,001 to $1 M
Level H. $1,000,001 to $2.5 M
Level I. Greater than $2.5 M

All Volume Indexes from Volume 1, Number 1 to the present are available ONLINE at the journal’s full-text website at www.TheSpineJournalOnline.com. Author Instructions are also available there.